En español

Messages From the Director

NIDA Funding Priorities

NIDA Director Nora Volkow

May 2011


In these tough budget times, it is not surprising that rumors will take hold about where we will direct our funding priorities at NIDA. To counter with facts, I would like to reassure all of our research grantees that our priorities remain the same—that is, a focus on prevention, treatment, and HIV—and that no one aspect of NIDA's multilayered research portfolio will be neglected to the enhancement of others. It has been rumored, for example, that medications development will capture an inequitable portion of our budget; however, this is not true. While medications development is a critical piece of the research we fund, particularly since pharmaceutical companies have been reluctant to invest, it reflects only 12 percent of our total budget, a rate relatively unchanged over the last several years. Please know that I appreciate the work of all of our grantees and am keenly aware that it takes all of your varied contributions to carry out NIDA's mission "to lead the Nation in bringing the power of science to bear on drug abuse and addiction."

FY10 Funding, Basic & Clinical Neuroscience & Behavioral, 47%; Epidemiology and Prevention, 23%; Pharmacotherapies, 12%; Clinical Trials, 4%; IRP, 8%; Management, 6%


Nora D. Volkow, M.D.

This page was last updated May 2011

Messages from the Director

Mar 2013

Feb 2013

Jan 2013

Jan 2013

Dec 2012

Nov 2012

Nov 2012

Nov 2012

Mar 2012

Mar 2012

Feb 2012

Nov 2011

Sep 2011

Aug 2011

Jun 2011

May 2011

May 2011

Feb 2011

Jan 2011

Dec 2010

Oct 2010

Apr 2010

Dec 2009

May 2009

Feb 2009

Dec 2008

Sep 2008

Aug 2008

Jan 2008

May 2007

May 2007

Feb 2007

Jul 2006

Jun 2006

Oct 2005

Sep 2005

Aug 2005

Apr 2005

Mar 2005

Apr 2004

Mar 2004

Mar 2004